Clinical Trial Update: Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer [Phase 2]

View source ↗

Summary

A Phase II trial evaluating erlotinib hydrochloride in patients with advanced esophageal cancer and gastroesophageal junction cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Esophagus
• Adenocarcinoma of the Gastroesophageal Junction
• Esophageal Cancer
• Squamous Cell Carcinoma of the Esophagus

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction | Phase 2 | Status: COMPLETED